Research | Clinical Trials | Clinical Trial Details Page

GABA-glutamate Interactions and Psychosis

Conditions

Cognitive Dysfunction

Trial Phase

Phase 1/Phase 2

Trial Purpose and Description

Trial Purpose

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.


Participation Guidelines

Age:
21 Years - 45 Years
Gender:
Both

Eligibility Criteria


Inclusion criteria:

- Ages of 21-45 years from all ethnic backgrounds.

- Male or female.

- Written informed consent.

Exclusion criteria:

- DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.

- A history of significant medical/neurological disease such as cardiac, thyroid,
renal, hepatic abnormality, seizure disorder. Unstable medical condition based on
EKG, vital signs, physical examination and laboratory work-up (CBC with differential,
SMA-7, LFTs, TFTs, UA, Utox).

- History of abnormal EEG.

- History of severe allergies or multiple adverse drug reactions.

- Any medication that could interfere with either the safety of the study and/or the
outcome measures.

- Any other conditions which in the opinion of the investigator would preclude
participation in the study.

- History of major psychiatric disorder in first degree relatives.

- Current substance abuse/dependency determined by urine toxicology.

- Treatment with medications with CNS effects.

- Treatment with benzodiazepines within one week prior to testing.

- Current treatment with medications with psychotropic effects.

- Education < 10th grade.

- IQ < 70, MR.

- Non-English speaking.
Sponsor:
National Alliance for Research on Schizophrenia and Depression
Yale University
Dates:
January 2007
Last Updated:
May 17, 2012
Study HIC#:
0508000517

Clinicaltrials.gov ID: NCT00611572